期刊文献+

四联疗法和三联疗法治疗十二指肠溃疡的疗效比较

Clinical Effects of Quadruple and Triple Chemotherapy for the Treatment with Duodenal Ulcer
下载PDF
导出
摘要 目的对比含呋喃唑酮及胶体果胶铋的四联疗法和经典三联疗法对十二指肠溃疡(DU)幽门螺杆菌感染(HP)初治者的疗效。方法选择有HP感染的十二指肠溃疡(DU)患者86例,随机均分为治疗组和对照组。治疗组选择埃索美拉唑+阿莫西林+呋喃唑酮+胶体果胶铋四联疗法,疗程10d;对照组选择埃索美拉唑+阿莫西林+克拉霉素经典三联疗法,疗程10d。观察HP的根除率和不良反应情况。结果含呋喃唑酮及胶体果胶铋的四联疗法与经典三联疗法的HP根除率分别为90.1%、79.1%,差异有显著性(P<0.05)。十二指肠溃疡治疗总有效率差异无显著性(P>0.05)。结论含呋喃唑酮及胶体果胶铋的四联疗法根除幽门螺杆菌感染安全、有效。 Objective Clinical Study Comparison the effects of Furaxone and Pectin Bismuth-based quadruple chemotherapy and triple chemotherapy for the treatment eradication of helicobacter pylori (HP) in patients with duodenal ulcer. Methods 86 patients with HP infection accompanied with duodenal ulcer were randomly divided into treatment group and control group. The patients in treatment group were given Esomeprazole, Amoxicillin, Furaxone and Pectin Bismuth for 10 days, while in control group received Esomeprazole, Amoxicillin and Clarithromycin. The condition of HP eradication and side-effects were erahuated. Results The two therapies were effective and safe. The eradication rates of HP in treatment group were significantly higher than that in control group (90.1% vs 79.1%), (P〈0.05). The total effective rate in patients with duodenal ulcer were no significant difference (P〉0.05). Conclusion The quadruple therapy of Esomeprazole, Amoxicillin, Furaxone and Pectin Bismuth is a safe and effective choice for HP eradication.
作者 张莉 代小松
出处 《中国医药指南》 2013年第7期20-21,共2页 Guide of China Medicine
关键词 呋喃唑酮 胶体果胶铋 十二指肠溃疡 幽门螺杆菌 Furaxone Pectin Bismuth Duodenal ulcer Helicobacter pylori
  • 相关文献

参考文献14

  • 1张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民.幽门螺杆菌共识意见(2003·安徽桐城)[J].中华消化杂志,2004,24(2):126-127. 被引量:438
  • 2Malfertheiner P,Megraud FO,Morain C,et al.Current concepts inthe management of Helicobacter pylori infection:The MaasrichtⅢConsensus Reoport[J].Gut,2007,56(6):772-781.
  • 3张玲霞,张沥,马京玲,宋瑛.荆花胃康联合PPI三联治疗幽门螺杆菌阳性慢性胃炎临床疗效观察[J].内蒙古中医药,2010,29(22):21-22. 被引量:8
  • 4Kim BG,Lee DH,Ye BD,et al.Comparison of 7-days and 14-daysProton pump inhibitor-containing triple therapy for Helicobacterpylori eradication rate in Korea[J].Helicobacter,2007,12(1):31-35.
  • 5第三次全国幽门螺杆菌感染若干问题共识报告(2007年8月庐山)[J].中华医学杂志,2008,88(10):652-656. 被引量:103
  • 6胡品津.规范幽门螺杆菌感染的诊断和治疗[J].中华内科杂志,2004,43(4):243-243. 被引量:78
  • 7Yan X,Zhou L,Song Z,et al.Sequential therapy for helicobacterpylori eradication in adults compared with triple therapy in china:a multiplecenter,prospective,randomized,controlled trial[J].Helicobacter,2011,16(1):87.
  • 8H.pylori Group of Chinese Society of Gastroenterology/Natio-nalH.Pylori Scientific Research Cooperative Group.Prevalence ofhelicobacter pylori resistance to antibiotics and its in fluence onthe treatrment outcome in China:a multicenter clinical study[J].Chin J Gastroenterol,2007,12(9):525-530.
  • 9De Francesco V,Margiotta M,Zullo A,et al.Prevalence of primaryclarithromycin res istance in Helicobacter pylori strains over a 15year period in Italy[J].J An timicrob Chem other,2007,59(4):783-785.
  • 10Zheng Q,Chen WJ,Lu H,et al.Comparison of the efficacy of tripleversus quadruple therapy on the eradication of Helicobacter pyloriand antibiotic resistance[J].J Dig Dis,2010,11(5):313-318.

二级参考文献34

共引文献615

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部